CCChrystelle Chemaly

Chrystelle Chemaly

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chrystelle Chemaly has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Refractory severe aplastic anemia in a child: treatment failure and access barriers in a low-resource setting

    by Zeinab Karaki, Chrystelle Chemaly, Jana Kotaich, Ali Shmeis, Raghida Dhayni

    Introduction and importance: Aplastic anemia (AA) is a rare but potentially fatal hematologic disorder in children, marked by bone marrow failure and pancytopenia. Early diagnosis and access to curative treatment such as hematopoietic stem cell transplantation (HSCT) are crucial. In low-resource settings, limited access to HSCT poses significant challenges. Case presentation: We present a 7-year-old girl with spontaneous ecchymoses and purpura following an upper respiratory infection. Laboratory tests revealed severe pancytopenia, and bone marrow biopsy showed <5% cellularity, consistent with severe AA. Infectious, autoimmune, and malignant causes were excluded. She received immunosuppressive therapy with rabbit anti-thymocyte globulin, cyclosporine A, and corticosteroids but failed to show hematologic recovery. HSCT was not an option due to financial constraints, and she remained transfusion-dependent. Clinical discussion: AA is often immune-mediated, and IST is a standard option when HSCT is unavailable. However, responses vary, particularly in pediatric cases. This case illustrates the limited effectiveness of IST in some patients and highlights how socioeconomic barriers hinder access to definitive treatment, impacting outcomes. Conclusion: This case underscores the urgent need for affordable curative therapies like HSCT in low-income settings. It also emphasizes the variable response to IST and the role of systemic inequities in limiting care for children with life-threatening hematologic diseases.


  • Open Access

    Therapy-related acute myeloid leukemia following aggressive treatment for pediatric medulloblastoma: a case report of a 13-year-old and review of literature

    by Zeinab Karaki, Jana Kotaich, Chrystelle Chemaly, Mohamad Mourad, Rhaghida Dhayni

    Introduction and importance: Medulloblastoma (MBL) is the most common malignant brain tumor in children, accounting for up to 25% of primary central nervous system neoplasms. Standard treatment includes surgical resection, chemotherapy, and craniospinal irradiation (CSI). While these multimodal therapies have significantly improved survival, they are associated with long-term toxicities. One rare but serious complication is therapy-related acute myeloid leukemia (t-AML), which results from exposure to cytotoxic chemotherapy and/or radiotherapy. t-AML is known for its poor prognosis, low treatment response, and increased toxicity, making it a particularly challenging outcome in pediatric oncology. Case presentation: We present the case of a pediatric patient with medulloblastoma who experienced three disease relapses. During treatment with etoposide for recurrent medulloblastoma, the patient developed t-AML. Despite the typically poor outcomes associated with t-AML, the patient achieved remission from leukemia. However, medulloblastoma remained refractory. Clinical discussion: This case highlights the dual burden of disease recurrence and secondary malignancy in pediatric oncology patients. The development of t-AML following etoposide therapy raises important considerations about cumulative treatment-related risks. While remission of t-AML was successfully achieved, the ongoing progression of medulloblastoma underscores the complexity of managing patients with multiple, concurrent oncologic challenges. It also calls attention to the limitations of current therapeutic approaches in preventing and treating long-term complications. Conclusion: The case underscores the importance of vigilant long-term follow-up and surveillance for hematologic abnormalities in medulloblastoma patients, especially those exposed to high-risk chemotherapeutic agents. Early detection and intervention for therapy-related complications like t-AML are essential to optimize care, even as the primary malignancy may continue to progress.